GenorBio partners with MabSpace Biosc...
Home  »  Community News  »  GenorBio partners wi...
GenorBio partners with MabSpace Biosciences to develop novel antibody therapeutics
Pharma News
, ,

MabSpace Biosciences Co., Ltd, a biotechnology company focused on the discovery and early development of antibody based therapeutics,  has signed a collaborative contract of a novel therapeutic antibody with Genor Biopharma Co. Ltd (GenorBio), the mAb division of Walvax Group, one of the leading therapeutic antibody development companies in China.

According to the agreement, MabSpace will be responsible for the discovery and selection of fully human lead antibodies and GenorBio for the further development of the selected candidate molecules. GenorBio will own exclusive global rights on the resulting therapeutic candidates for the nominated targets, while MabSpace will receive upfront R&D funding, regulatory milestones and royalty on global sales.

“We are attracted by MabSpace’s capability in discovering novel differentiated antibody therapeutic candidates with its immune tolerance breaking technology and the access to fully human antibody transgenic mice platform,” commented Dr. Joe Zhou, CEO of Genor Biopharma and VP of Research of Walvax Group.

“MabSpace is honored to work with GenorBio who has extensive capabilities and experience in antibody process and product development,” said Dr. Xueming Qian, Chairman and CEO of MabSpace.

Leave a reply

You must be logged in to post a comment.